

Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	18,757,159
Number of real voting rights* (excluding treasury shares**)	18,695,888
Theoretical number of voting rights* (including treasury shares**)	18,733,959

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations



About Median Technologies: Pioneering innovative imaging services and software as a medical device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S.

and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts

Median Technologies

Emmanuelle Leygues
VP, Corporate Marketing & Financial
Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press - ALIZE RP

Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investors - ACTIFIN

Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com